Difference between revisions of "SPECT Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 24: Line 24:
  
 
==Profile Development==
 
==Profile Development==
 +
 +
*[[Media:Draft Profile Section on Image Analysis 3.10.docx | QIBA DRAFT Profile Section 3.10 on Image Analysis - {Drs. Miyaoka and Seibyl}]] ''March 8, 2016''
  
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.02.17.docx | QIBA DRAFT Profile: Quantifying Dopamine Transporters with 123-Iodine Labeled Ioflupane in Neurodegenerative Disease - {comments from Mr. Cella}]] ''February 17, 2016''
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.02.17.docx | QIBA DRAFT Profile: Quantifying Dopamine Transporters with 123-Iodine Labeled Ioflupane in Neurodegenerative Disease - {comments from Mr. Cella}]] ''February 17, 2016''

Revision as of 21:08, 8 March 2016

Project Snapshot

The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.


Under consideration:

  • quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
  • quantifying organs, like the liver, for dosimetry as potential use cases


Established Task Forces Currently Working Toward a first Profile with title as follows below:

Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease

  • Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
  • Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
  • Phantoms / DRO Group – Drs. Dickson and Zimmerman
  • Clinical / Literature Review – Dr. Seibyl

Meetings/Call Summaries


Working Documents

Profile Development

Archived versions of the Profile

Statistical Reference Documents

Workflow Documents

Reference Materials